11，The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development diabetes mellitus. N Eng J Med, 1993, 329:977～986
22，UK Prospective Diabetes study(UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type Ⅱ diabetes. Lancet, 1998,352:837
46，Deferrari G, Repetto M, Calvi C, et al. Diabetic nephropathy: from micro-to macroalbuminuria. Nephrol-Dial-Transplant， 1998，13(suppl)8:11～15
57，Cooper ME. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type Ⅰ and type Ⅱdiabetic patients J-Hypertens-suppl,1996,14:S11～14
69，De Gasparo M, Whitebread S. Binding of valsartan to mammatian angiotensin AT, receptors. Regul Pept, 1995,59:303～309
710，Sheinfeld GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagouist therapy for diabetic patients. Am-J-Hypertens,1999, 12:80～85
811，Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia,1999,42:579～588
912，Zalevskaia AG, Astamirova Khs, Karpova IA, et al. A trial of the use of the Low-molecular heparin sulodexide in the therapy of diabetic nephropathy. Ter-Arkh, 1998,70:71～74
